XERS
Xeris Biopharma Holdings, Inc.
$6.19
-0.19
(-2.98%)
Mkt Cap
1.07B
Volume
1,054,441
52W Range
4.3-10.08
Sector
Healthcare
Beta
0.92
EPS (TTM)
0.07
P/E Ratio
87.43
Revenue (TTM)
314.85M
Rev Growth (5Y)
+70.2%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
$16.14
Undervalued · Strong
61.7% below fair value
AlphaQuality · Grade · Gated
F
High-Growth Software
30.0 / 100 pillar composite (overridden)
Company Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 291.85M | 203.07M | 163.91M | 110.25M | 49.59M | 20.43M | 2.72M | 2.46M | 1.56M | 1.07M |
| Net Income | 554,000 | (54.84M) | (62.26M) | (94.66M) | (122.72M) | (91.14M) | (125.58M) | (60.08M) | (26.55M) | (13.21M) |
| EPS | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 | -3.49 | -4.99 | -13.09 | -7.17 |
| Free Cash Flow | 27.93M | (37.85M) | (49.29M) | (103.42M) | (103.42M) | (96.62M) | (80.94M) | (57.79M) | (25.36M) | (16.12M) |
| FCF / Share | 0.17 | -0.26 | -0.36 | -0.76 | -1.31 | -2.27 | -3.10 | -4.80 | -12.51 | -8.75 |
| Operating CF | 28.63M | (36.98M) | (47.02M) | (102.89M) | (102.89M) | (95.53M) | (80.56M) | (56.28M) | (24.66M) | (16.09M) |
| Total Assets | 383.53M | 323.06M | 322.60M | 344.52M | 304.36M | 159.15M | 108.99M | 120.03M | 45.00M | 33.53M |
| Total Debt | 37.76M | 271.45M | 229.19M | 198.06M | 88.07M | 87.02M | 58.30M | 31.89M | 0 | 0 |
| Cash & Equiv | 111.04M | 71.62M | 67.45M | 121.97M | 67.27M | 37.60M | 19.52M | 45.72M | 42.05M | 32.27M |
| Book Value | 13.69M | (29.61M) | (6.78M) | 45.19M | 95.23M | 33.76M | 14.44M | 75.41M | (57.83M) | (31.93M) |
| Return on Equity | 0.04 | N/A | N/A | -2.09 | -1.29 | -2.70 | -8.70 | -0.80 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83.13M | 85.81M | 74.38M | 71.54M | 60.12M | 60.10M | 54.27M | 48.06M | 40.64M | 44.39M | 48.32M | 38.01M |
| Net Income | 2.23M | 11.08M | 621,000 | (1.93M) | (9.22M) | (5.11M) | (15.74M) | (15.01M) | (18.98M) | (13.39M) | (12.19M) | (19.84M) |
| EPS | 0.01 | 0.07 | 0.00 | -0.01 | -0.06 | -0.03 | -0.11 | -0.10 | -0.14 | -0.10 | -0.09 | -0.14 |
| Free Cash Flow | 9.54M | 19.71M | 18.07M | (97,000) | (10.04M) | 1.75M | (8.39M) | (10.74M) | (20.47M) | 6.15M | (14.96M) | (15.29M) |
| FCF / Share | 0.06 | 0.12 | 0.10 | -0.00 | -0.07 | 0.01 | -0.06 | -0.07 | -0.15 | 0.04 | -0.11 | -0.11 |
| Operating CF | 9.87M | 20.04M | 18.43M | 182,000 | (10.03M) | 1.98M | (8.30M) | (10.35M) | (20.30M) | 6.29M | (14.61M) | (13.74M) |
| Total Assets | 392.01M | 383.53M | 370.19M | 334.69M | 315.45M | 323.06M | 321.10M | 331.73M | 336.62M | 322.60M | 327.78M | 328.78M |
| Total Debt | 37.33M | 37.76M | 38.19M | 257.22M | 268.75M | 271.45M | 270.96M | 269.80M | 268.69M | 229.19M | 227.94M | 224.99M |
| Cash & Equiv | 111.75M | 111.04M | 91.60M | 59.28M | 58.44M | 71.62M | 59.23M | 57.60M | 62.69M | 67.45M | 46.14M | 46.17M |
| Book Value | 13.01M | 13.69M | (861,000) | (19.30M) | (35.13M) | (29.61M) | (28.32M) | (19.29M) | (9.18M) | (6.78M) | 3.87M | 13.64M |
| Return on Equity | 0.17 | 0.81 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -3.15 | -1.45 |
XERS News
Xeris Biopharma Q1 Earnings Call Highlights
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Xeris Biopharma Reports First Quarter 2026 Financial Results
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript